Management of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials

June 2021 | Volume 20 | Issue 6 | Original Article | 634 | Copyright © June 2021


Published online May 14, 2021

James Q. Del Rosso DO,a Linda Stein Gold MD,b Hilary Baldwin MD,c Julie C. Harper MD,d Joshua Zeichner MD, e Sabine Obagi,f Emmy Graber MD MBA,g Xochitl Jimenez MD,h Francisco Hernandez Vicente,i Ayman Grada MD MHAj

aJDR Dermatology Research/Thomas Dermatology, Las Vegas, NV
bDermatology Clinical Research, Henry Ford Health System, Detroit, MI
cDepartment of Dermatology, Acne Treatment & Research Center, Morristown, NJ
dDermatology and Skin Care Center of Birmingham, Birmingham, AL
eMount Sinai Hospital, New York, NY
fBoston University School of Medicine, Boston, MA
gDermatology Institute of Boston, Boston, MA; Northeastern University, Boston, MA
hMedical Affairs, Almirall LLC., Exton, PA IGlobal Clinical Statistics, Almirall SA., Barcelona, Spain
jR&D and Medical Affairs, Almirall LLC., Exton, PA






vs 7.71%, respectively; P=0.0192), week 6 (18.81% vs 14.03%, respectively; P=0.0390), and week 12 (33.42% vs 20.77%, respectively; P<0.0001) for chest acne (Table 2; Figure 2C). IGA success at week 9 was numerically higher, but not significantly different in the sarecycline group compared to the placebo group (25.07% vs 20.21%, respectively; P=0.0759).

Pooled IGA Success in Back Acne
In the individual studies, IGA success rate was significantly greater in the sarecycline group compared to the placebo group at weeks 3 (10.6% vs 5.2%, respectively; P=0.011), 6 (17.5% vs 10.9%, respectively; P=0.046), 9 (28.1% vs 17.2%, respectively; P=0.006) and 12 (32.9% vs 17.1%, respectively; P<0.001) for